Charles River Laboratories International, Inc. (CRL) closed Tuesday at $335.63, a decline of 0.69% on the day. The contract research organization carries a market capitalization of $16.19 billion.
The modest daily pullback extends a softer stretch over the past week, with shares down 4.95% over the trailing seven-day period. The near-term pressure follows what had been a strong run for the stock.
Despite the recent headwinds, CRL has gained 11.74% over the past 30 days, reflecting a meaningful recovery over that longer window. The 30-day advance leaves the stock comfortably above the levels seen at the start of that period.
The combination of a strong monthly gain and a week of consolidation suggests the shares have been digesting their earlier move, though the data alone does not point to a clear directional catalyst.



